18
Participants
Start Date
January 31, 2016
Primary Completion Date
September 30, 2022
Study Completion Date
September 30, 2022
Immunoglobulins, Intravenous (Privigen)
Placebo
Grampian Health Board, Aberdeen
Birmingham Children's Hospital NHS Foundation Trust, Birmingham
Heart of England NHS Foundation Trust, Birmingham
University Hospitals Bristol NHS Foundation Trust, Bristol
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Hull and East Yorkshire Hospitals NHS Trust, Hull
Leeds Teaching Hospitals NHS Trust, Leeds
Barts Health NHS Trust, London
St George's University Hospitals NHS Foundation Trust, London
Central Manchester University Hospitals NHS Foundation Trust, Manchester
The Pennine Acute Hospitals NHS Trust, Manchester
University Hospital Southampton NHS Foundation Trust, Southampton
University Hospitals of North Midlands NHS Trust, Stoke-on-Trent
York Teaching Hospital NHS Foundation Trust, York
Tayside Health Board, Dundee
Lothian Health Board, Edinburgh
Alder Hey Children's NHS Foundation Trust, Liverpool
Guy's and St Thomas's NHS Foundation Trust, London
Imperial College Healthcare NHS Trust, London
Great Ormond Street Hospital, London
South Tees Hospitals NHS Foundation Trust, Middlesbrough
Nottingham University Hospitals NHS Trust, Nottingham
Oxford University Hospitals NHS Foundation Trust, Oxford
Sheffield Children's NHS Foundation Trust, Sheffield
Royal Cornwall Hospitals NHS Trust, Truro
Collaborators (1)
National Institute for Health Research, United Kingdom
OTHER_GOV
CSL Behring
INDUSTRY
University of Liverpool
OTHER
University College London Hospitals
OTHER
Guy's and St Thomas' NHS Foundation Trust
OTHER
Liverpool University Hospitals NHS Foundation Trust
OTHER_GOV
Great Ormond Street Hospital for Children NHS Foundation Trust
OTHER
University of Oxford
OTHER